IL17A and metabolic dysfunction-associated steatotic liver disease: Obesity-induced hepatic Th17 cells and IL-17A signaling have consistently been reported to impair insulin sensitivity and promote hepatic steatosis and fibrosis in both HFD-fed mice and patients with NAFLD/NASH (12–16, 50–52).